Capecitabine(Aibin)

DRUG3 trials

Sponsors

The First Affiliated Hospital of Henan University of Science and Technology

Conditions

Esophageal NeoplasmsStage II Esophageal Squamous Cell CarcinomaStage III Esophageal Squamous Cell Carcinoma

Phase 3

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer

The First Affiliated Hospital of Henan University of Science and TechnologyStage II Esophageal Squamous Cell Carcinoma, Stage III Esophageal Squamous Cell Carcinoma

Start: 2014-10-31End: 2025-04-01Updated: 2023-02-08

Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy

The First Affiliated Hospital of Henan University of Science and TechnologyStage II Esophageal Squamous Cell Carcinoma, Stage III Esophageal Squamous Cell Carcinoma

Start: 2014-10-31End: 2019-12-31Target: 200Updated: 2015-11-11

The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy

The First Affiliated Hospital of Henan University of Science and TechnologyEsophageal Neoplasms, Stage III Esophageal Squamous Cell Carcinoma

Start: 2014-10-31End: 2020-12-31Target: 60Updated: 2016-07-06

Related Papers

X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local-advanced squamous esophageal cancer (ESCC): 2021 update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Journal of Clinical Oncology2022-01-19

X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Journal of Clinical Oncology2020-05-20

A randomized, open-label, multicenter trial of the concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with 5-FU for Chinese squamous esophageal cancer: An interim report from CRTCOESC.

Journal of Clinical Oncology2017-05-203 citations